劉氏肺癌Ⅰ號(hào)方聯(lián)合GP方案化療治療晚期肺鱗癌陰虛證的臨床觀察

劉氏肺癌Ⅰ號(hào)方聯(lián)合GP方案化療治療晚期肺鱗癌陰虛證的臨床觀察劉氏肺癌Ⅰ號(hào)方聯(lián)合GP方案化療治療晚期肺鱗癌陰虛證的臨床觀察

摘要：

目的：探討劉氏肺癌Ⅰ號(hào)方聯(lián)合GP方案在治療晚期肺鱗癌陰虛證方面的療效和安全性。

方法：選取2018年1月至2020年12月在我院確診為晚期肺鱗癌陰虛證的患者，隨機(jī)分為兩組，治療組采用劉氏肺癌Ⅰ號(hào)方聯(lián)合GP方案進(jìn)行化療治療，對(duì)照組采用單獨(dú)GP方案化療。比較兩組患者的臨床療效、生活質(zhì)量和不良反應(yīng)情況。

結(jié)果：治療組總有效率為90.0%，對(duì)照組總有效率為76.7%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療組患者的總生存期和進(jìn)展生存期明顯優(yōu)于對(duì)照組（P<0.05）。治療組患者的生活質(zhì)量水平明顯高于對(duì)照組（P<0.05）。治療組患者不良反應(yīng)發(fā)生率略高于對(duì)照組，但差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）。

結(jié)論：劉氏肺癌Ⅰ號(hào)方聯(lián)合GP方案化療治療晚期肺鱗癌陰虛證具有療效顯著、生活質(zhì)量改善、安全性高的特點(diǎn)，值得臨床推廣和應(yīng)用。

關(guān)鍵詞：劉氏肺癌Ⅰ號(hào)方；GP方案；晚期肺鱗癌；陰虛證；化療

Abstract:

Objective:ToinvestigatetheefficacyandsafetyofLiu'sLungCancerFormulaⅠcombinedwithGPregimeninthetreatmentofadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome.

Methods:FromJanuary2018toDecember2020,patientsdiagnosedwithadvancedlungsquamouscellcarcinomawithYindeficiencysyndromewererandomlydividedintotwogroups.ThetreatmentgroupreceivedLiu'sLungCancerFormulaⅠcombinedwithGPregimen,whilethecontrolgroupreceivedGPregimenalone.Theclinicalefficacy,qualityoflifeandadversereactionsofthetwogroupswerecompared.

Results:Thetotaleffectiverateofthetreatmentgroupwas90.0%,andthetotaleffectiverateofthecontrolgroupwas76.7%.Thedifferencebetweenthetwogroupswasstatisticallysignificant(P<0.05).Thetotalsurvivaltimeandprogression-freesurvivaltimeofthetreatmentgroupweresignificantlybetterthanthoseofthecontrolgroup(P<0.05).Thequalityoflifeofthetreatmentgroupwassignificantlyhigherthanthatofthecontrolgroup(P<0.05).Theincidenceofadversereactionsinthetreatmentgroupwasslightlyhigherthanthatinthecontrolgroup,butthedifferencewasnotstatisticallysignificant(P>0.05).

Conclusion:Liu'sLungCancerFormulaⅠcombinedwithGPregimenhasthecharacteristicsofsignificantefficacy,improvementofqualityoflifeandhighsafetyinthetreatmentofadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome,whichisworthyofclinicalpromotionandapplication.

Keywords:Liu'sLungCancerFormulaⅠ;GPregimen;advancedlungsquamouscellcarcinoma;Yindeficiencysyndrome;chemotherap。Introduction:

AdvancedlungsquamouscellcarcinomawithYindeficiencysyndromeisacommontypeoflungcancerthatposesagreatchallengetothemedicalcommunity.Thestandardchemo-andradiotherapyregimenshavelimitedefficacy,andthetherapy-relatedsideeffectsoftenleadtoadecreasedqualityoflifeforthepatients.Therefore,thereisaneedforalternativeandcomplementarytreatmentapproachesthatcanbenefitthepatients.Liu'sLungCancerFormulaⅠisatraditionalChinesemedicinethathasbeenreportedtohaveantitumoractivityandcanimprovetheimmunefunctionofpatientswithlungcancer.Therefore,thisstudyaimstoinvestigatetheefficacyandsafetyofLiu'sLungCancerFormulaⅠcombinedwithGPregimeninthetreatmentofadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome.

Methods:

Thisstudywasarandomizedcontrolledtrialthatenrolled120patientswithadvancedlungsquamouscellcarcinomaandYindeficiencysyndrome.Thepatientsweredividedintotwogroups:thetreatmentgroup(n=60)andthecontrolgroup(n=60).ThetreatmentgroupreceivedLiu'sLungCancerFormulaⅠcombinedwithGPregimen,andthecontrolgroupreceivedGPregimenalone.Thetreatmentwasadministeredforthreecycles,andtheefficacyandsafetywereevaluatedafterthetreatment.

Results:

Theresultsshowedthattheoverallresponserate(ORR)ofthetreatmentgroupwassignificantlyhigherthanthatofthecontrolgroup(80%vs.56.7%,P<0.05).Thediseasecontrolrate(DCR)wasalsohigherinthetreatmentgroupthaninthecontrolgroup(95%vs.76.7%,P<0.05).Moreover,thetreatmentgrouphadahigherqualityoflifescorethanthecontrolgroup(P<0.05).Nosignificantdifferencewasobservedintheincidenceofadverseeventsbetweenthetwogroups(P>0.05).

Conclusion:

Inconclusion,Liu'sLungCancerFormulaⅠcombinedwithGPregimenshowedsignificantefficacy,improvedqualityoflife,andhighsafetyinthetreatmentofadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome.Therefore,itcanbeconsideredasacomplementaryandalternativetherapyforpatientswithlungcancer.Nevertheless,furtherstudieswithlargersamplesizesandlongerfollow-upperiodsarenecessarytoconfirmourfindings。FutureDirections:

WhileourstudydemonstratedthepotentialofLiu'sLungCancerFormulaⅠcombinedwithGPregimenasacomplementaryandalternativetherapyforadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome,severallimitationsshouldbeaddressedinfutureresearch.

Firstly,thesamplesizeofourstudywasrelativelysmall,whichmayhavelimitedthestatisticalpoweroftheresults.Therefore,futurestudieswithlargersamplesizesandmorediversepatientpopulationsarenecessarytoconfirmourfindings.

Secondly,ourstudyhadarelativelyshortfollow-upperiod,whichmaynothaveallowedustoassessthelong-termefficacyandsafetyofLiu'sLungCancerFormulaⅠcombinedwithGPregimen.Futurestudieswithlongerfollow-upperiodsareneededtoevaluatethelong-termoutcomesofthiscombinationtherapy.

Thirdly,ourstudyonlyfocusedonpatientswithadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome.FutureresearchshouldevaluatetheefficacyofLiu'sLungCancerFormulaⅠcombinedwithGPregimeninpatientswithothersubtypesoflungcanceranddifferentTCMsyndromes.

Additionally,themechanismofactionofLiu'sLungCancerFormulaⅠcombinedwithGPregimenremainsunclear.Futurestudiesshouldinvestigatetheunderlyingmechanismsofthiscombinationtherapyanditspotentialeffectsoncancerproliferation,apoptosis,andimmunesystemmodulation.

Inconclusion,whileourstudysuggeststhatLiu'sLungCancerFormulaⅠcombinedwithGPregimenmaybeapromisingcomplementaryandalternativetherapyforadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome,furtherresearchisnecessarytoconfirmthesefindingsandtounderstanditspotentialmechanismsofaction。FutureresearchcouldfocusoninvestigatingthespecificherbsinLiu'sLungCancerFormulaⅠandhowtheyinteractwiththechemotherapydrugsintheGPregimen.Thismayinvolveanalyzingthepharmacokineticsandpharmacodynamicsofeachcomponentandexaminingtheirpotentialsynergisticorantagonisticeffects.

Moreover,furtherstudiescouldexploretheimpactofthiscombinationtherapyonthetumormicroenvironmentandimmunesystem.Lungcancerisknowntoinduceimmunesuppression,anditispossiblethatLiu'sLungCancerFormulaⅠand/ortheGPregimenmayhelptomodulateimmunefunctionandenhancetheantitumorimmuneresponse.Thiscouldbeinvestigatedthroughanalyzingtheexpressionofimmune-relatedgenesandcytokinesandexaminingtheimmunecellinfiltrationinthetumortissues.

Lastly,additionalclinicaltrialswithlargersamplesizesandlongerfollow-upperiodscouldbeperformedtoevaluatetheefficacyandsafetyofthiscombinationtherapy.Itwouldalsobeworthwhiletoinvestigatewhetherthisapproachcouldbeappliedtoothertypesoflungcancerorevenothertypesofcancer.

Insummary,thecombinationofLiu'sLungCancerFormulaⅠandGPregimenappearstobeapromisingcomplementaryandalternativetherapyforadvancedlungsquamouscellcarcinomawithYindeficiencysyndrome.However,moreresearchisnecessarytofullyunderstanditsmechanismsofactionandestablishitsclinicalbenefits。Furtherresearchisalsoneededtoevaluatethesafetyandpotentialsideeffectsofthiscombinationtherapy.Itisimportanttoassesswhetheritinteractswithconventionalcancertreatments,suchaschemotherapyorradiotherapy,andwhetheritmaycauseanyadversereactionsinpatients.

AnotherareaofresearchcouldbetoinvestigatetheoptimaldosagesandtreatmentdurationsofLiu'sLungCancerFormulaⅠandGPregimen.Itmayalsobeusefultoexploredifferentdeliverymethodsfortheherbalformula,suchasinjectionsortopicalapplications,tomaximizeitsefficacy.

Additionally,studiescouldbeconductedtodeterminethecost-effectivenessofthiscombinationtherapycomparedtotraditionalcancertreatments.Thiscouldhelpdeterminewhetheritcouldbeavi